* Minerva Neurosciences Inc reported a quarterly adjusted loss of 54 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.03. The lone analyst forecast for the quarter was for a loss of $1.01 per share.
* Reported revenue was zero; analysts expected zero.
* Minerva Neurosciences Inc's reported EPS for the quarter was $2.97.
* The company reported quarterly net income of $22.51 million.
* Minerva Neurosciences Inc shares had fallen by 13.1% this quarter and lost 62.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "hold"
Wall Street's median 12-month price target for Minerva Neurosciences Inc is $5.00 This summary was machine generated from LSEG data November 6 at 04:59 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -1.01 -0.54 Beat
Jun. 30 2024 -0.97 -1.09 Missed
Mar. 31 2024 -1.20 -1.13 Beat
Dec. 31 2023 -0.88 -1.39 Missed
Comments